Skip to Content

Perspective Therapeutics Inc CATX

Morningstar Rating
$12.64 +0.75 (6.31%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

CATX is trading at a 727% premium.
Price
$12.52
Fair Value
$95.72
Uncertainty
Extreme
1-Star Price
$946.44
5-Star Price
$8.28
Economic Moat
Jxks
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CATX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$11.89
Day Range
$11.8712.87
52-Week Range
$2.0519.05
Bid/Ask
$11.00 / $12.82
Market Cap
$852.12 Mil
Volume/Avg
758,232 / 879,652

Key Statistics

Price/Earnings (Normalized)
Price/Sales
123.94
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Small Value
Total Number of Employees
119

Comparables

Valuation

Metric
CATX
ANAB
NYKD
Price/Earnings (Normalized)
Price/Book Value
3.2319.272.64
Price/Sales
123.9439.0938.19
Price/Cash Flow
Price/Earnings
CATX
ANAB
NYKD

Financial Strength

Metric
CATX
ANAB
NYKD
Quick Ratio
12.5211.208.43
Current Ratio
12.9811.538.43
Interest Coverage
−452.31−8.08
Quick Ratio
CATX
ANAB
NYKD

Profitability

Metric
CATX
ANAB
NYKD
Return on Assets (Normalized)
−31.84%−25.16%−18.26%
Return on Equity (Normalized)
−37.09%−101.95%−23.64%
Return on Invested Capital (Normalized)
−37.34%−87.63%−26.98%
Return on Assets
CATX
ANAB
NYKD
See how this stock stacks up to its competitors with Morningstar Investor

Medical Devices Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Abbott Laboratories
ABT
SgdgdwcsNkrcs$177.5 Bil
Stryker Corp
SYK
HscdyvghtJskl$129.9 Bil
Boston Scientific Corp
BSX
DssvxkdlMfjwqkt$114.0 Bil
Medtronic PLC
MDT
HtyjykbdVzvdcb$101.9 Bil
Edwards Lifesciences Corp
EW
SwzrwrffbDthpdpd$52.1 Bil
DexCom Inc
DXCM
QgzzfbmskmKfyy$44.2 Bil
Koninklijke Philips NV ADR
PHG
QyxqtfmChwldp$24.3 Bil
Zimmer Biomet Holdings Inc
ZBH
PdttfjcnjkCzcvl$22.7 Bil
Steris PLC
STE
NhqrzkmfhLgblnj$22.2 Bil
Align Technology Inc
ALGN
HwdrsklMszyv$18.9 Bil

Sponsor Center